<DOC>
	<DOCNO>NCT01622504</DOCNO>
	<brief_summary>This study aim compare pharmacokinetics naloxone administer Mitovie nasal spray ( Test Product ) solution injection ( Comparator Product ) administer intranasally use mucosal atomization device ( MAD ) .</brief_summary>
	<brief_title>Naloxone Nasal Spray Pharmacokinetic Study</brief_title>
	<detailed_description>Naloxone hydrochloride currently recommend license intravenous , intramuscular subcutaneous administration . It also use intranasal administration ( off-label use ) intravenous route suitable administer Solution Injection use mucosal atomization device ( MAD ) . However , due volume naloxone solution administer way , may inadvertently swallow absorbed nasal mucosa product require administration medically trained personnel . The study aim investigate intranasal administration naloxone use concentrated solution nasal delivery device .</detailed_description>
	<mesh_term>Drug Overdose</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Male female 1860 50 year age Provide write informed consent prior complete study specific procedure . Body Mass Index ( BMI ) range 18.530 kg/m2 Clinically acceptable medical history , clinical laboratory evaluation , complete physical examination , vital sign 12 lead ECG Using reliable contraception Intranasal problem Taking prescribed counter medication Intake alcohol , methylxanthines grapefruit strenuous exercise concurrent treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Intranasal</keyword>
	<keyword>nasal spray</keyword>
	<keyword>opioid</keyword>
	<keyword>overdose</keyword>
</DOC>